First-stage clear-cell endometrial carcinoma with paraaortic lymph node recurrence: a case report.
adjuvant treatment
clear-cell endometrial carcinoma
surgical management
Journal
Przeglad menopauzalny = Menopause review
ISSN: 1643-8876
Titre abrégé: Prz Menopauzalny
Pays: Poland
ID NLM: 101263235
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
22
06
2020
accepted:
19
09
2020
entrez:
3
5
2021
pubmed:
4
5
2021
medline:
4
5
2021
Statut:
ppublish
Résumé
Endometrial cancer (EC) is the sixth most common malignancy in women worldwide; in developed countries this oncological entity climbs to fourth place. In 2012 worldwide 319 600 new cases were registered and about 1/3 of those were diagnosed in Europe, i.e. more than 100 000 cases. Statistics in Bulgaria show an increase in the incidence; the National Cancer Registry reported an incidence rate of 8.6% for 2013, with 1293 new cases; about 300 women die because of this diagnosis every year. Clear-cell endometrial carcinoma (EC) is relatively rare, in 1-6% of cases, with significantly shorter survival rates even for early stages (I and II), compared to the other histological subtypes. A 62-year-old patient was subjected to surgery for clear-cell endometrial carcinoma, stage pT1N0M0, FIGO stage IA. Despite radical surgical treatment as per Bulgarian oncological standards - total hysterectomy with bilateral adnexectomy and pelvic lymph node dissection with postoperative radiotherapy - there was a recurrence in a the paraaortic lymph node 15 months later. A second surgical intervention with radical resection of the parailiac metastatic lymph nodes on the left was done with subsequent pseudo-adjuvant platinum-based chemotherapy, and no further relapse has occurred 36 months later. Clear-cell EC is an aggressive disease with worse prognosis than the endometroid subtype. Therefore, comprehensive surgery and surgical staging should be performed, including pelvic and paraaortic lymph node dissection, regardless of stage.
Identifiants
pubmed: 33935622
doi: 10.5114/pm.2021.105273
pii: 43823
pmc: PMC8077803
doi:
Types de publication
Case Reports
Langues
eng
Pagination
57-60Informations de copyright
Copyright © 2021 Termedia.
Déclaration de conflit d'intérêts
The authors report no conflict of interest.
Références
Updates Surg. 2017 Sep;69(3):383-388
pubmed: 28466456
Am J Obstet Gynecol. 2020 Oct;223(4):605-606
pubmed: 32497607
Pathol Oncol Res. 2020 Oct;26(4):2281-2289
pubmed: 32462419
Gynecol Oncol. 1995 Aug;58(2):198-201
pubmed: 7622105
J Clin Oncol. 1993 Mar;11(3):485-90
pubmed: 8383191
Gynecol Oncol. 2006 Apr;101(1):120-5
pubmed: 16307792
Gynecol Oncol. 1991 Mar;40(3):207-17
pubmed: 2013441
Gynecol Oncol. 2008 Feb;108(2):293-7
pubmed: 18096208
Am J Surg Pathol. 2006 Dec;30(12):1519-30
pubmed: 17122507
Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):767-78
pubmed: 11020574
Acta Cytol. 2001 Jul-Aug;45(4):555-60
pubmed: 11480718
Am J Surg Pathol. 1995 Jul;19(7):769-74
pubmed: 7793474
Gynecol Oncol. 2004 Dec;95(3):593-6
pubmed: 15581969
Updates Surg. 2017 Mar;69(1):75-82
pubmed: 28108938
Int J Gynecol Pathol. 2020 Nov;39(6):522-528
pubmed: 31651558
Gynecol Oncol. 2009 May;113(2):277-83
pubmed: 19251307
Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):527-35
pubmed: 12243832
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Bull Cancer. 2007 Jan;94(1):E1-4
pubmed: 17236998